Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988956 | 0.85 | CA2 (0.50) | CA1CA2CA9CA12CA14 | |
| SCHEMBL407413 | 0.85 | CA2 (0.50) | CA1CA2CA9CA12CA14 | |
| Hydrochloric Acid SCHEMBL3517386 | 0.84 | CA1 (0.49) | CA1CA2CA9CA12CA14 | |
| Methane SCHEMBL28850761 | 0.84 | CA2 (0.49) | CA1CA2CA9CA12CA14 | |
| SCHEMBL6121437 | 0.83 | CA1 (0.45) | CA1CA2CA9CA12CA14 | |
| SCHEMBL3853253 | 0.80 | CA1 (0.50) | CA1CA2CA9CA12CA14 | |
| SCHEMBL4664432 | 0.79 | CA1 (0.42) | CA1CA2CA9CA12CA14 | |
| SCHEMBL22675719 | 0.79 | CALM1 (0.52) | HTR2ACYP2C9BCL2BCL2L1 | |
| SCHEMBL4662822 | 0.79 | LMNA (0.43) | CA1CA2CA9CA12CA14 | |
| SCHEMBL3837666 | 0.79 | CA1 (0.41) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| CN-101301294-A | Combinated inhibitors of FBP-ase and antidiabetic agents for diabetes treatment | METABEHJSIS TERAP JUTIKS INK (US) | 2008-11-12 | — | — | CN | disclosed |
| CN-100396283-C | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-1599612-A | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2005-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | CA1 2648/4885CA2 974/4885CA9 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.